CytRx Corporation Stock Nasdaq
Equities
US2328283013
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
06-04 | LadRx Corporation and ImmunityBio, Inc. Mutually Agree to Terminate Aldoxorubicin License | CI |
05-15 | LadRx Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2022 | - | Sales 2023 | - | Capitalization | 644K 885K |
---|---|---|---|---|---|
Net income 2022 | -4M -5.5M | Net income 2023 | - 0 | EV / Sales 2022 | - |
Net cash position 2022 | 1.15M 1.57M | Net cash position 2023 | 2.04M 2.8M | EV / Sales 2023 | - |
P/E ratio 2022 |
-1.05
x | P/E ratio 2023 |
1.91
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 99.44% |
Managers | Title | Age | Since |
---|---|---|---|
Stephen Snowdy
CEO | Chief Executive Officer | 55 | 22-01-09 |
John Caloz
DFI | Director of Finance/CFO | 72 | 07-09-30 |
Cristina Newman
SEC | Corporate Secretary | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Jennifer Simpson
CHM | Chairman | 55 | 21-07-28 |
Cary Claiborne
BRD | Director/Board Member | 64 | 22-07-26 |
Joel Caldwell
BRD | Director/Board Member | 69 | 17-07-11 |
1st Jan change | Capi. | |
---|---|---|
+48.54% | 56.61B | |
+37.15% | 39.25B | |
-6.02% | 39.62B | |
-6.90% | 28.28B | |
+12.97% | 26.44B | |
-16.91% | 20.12B | |
+31.71% | 12.48B | |
+28.18% | 12.51B | |
+0.38% | 12.2B |